Promising Growth and Innovation Drive Buy Rating for Niagen Bioscience

Canaccord Genuity analyst Susan Anderson has maintained their bullish stance on NAGE stock, giving a Buy rating yesterday.

Susan Anderson’s rating is based on Niagen Bioscience’s promising growth prospects and innovative approach in the health and wellness sector. The company is capitalizing on the increasing consumer interest in NAD+ levels, which are crucial for healthy aging, and is in the early stages of expanding its product pipeline globally.
Niagen Bioscience’s revenue is primarily driven by its Tru Niagen supplement line, and the recent launch of Niagen Plus, an IV and injectable business, is showing rapid growth. The company is also exploring pharmaceutical applications through clinical studies, including potential treatments for rare diseases. Additionally, the absence of tariff exposure and the company’s commitment to maintaining high standards in the supplement industry further support the Buy rating.

Anderson covers the Consumer Cyclical sector, focusing on stocks such as Ulta Beauty, Sally Beauty, and Peloton Interactive. According to TipRanks, Anderson has an average return of 17.2% and a 44.22% success rate on recommended stocks.

In another report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $11.00 price target.